Kindred Biosciences
KIN
KIN was delisted on the 27th of August, 2021.
71 hedge funds and large institutions have $241M invested in Kindred Biosciences in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 22 reducing their positions, and 19 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 22
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.77% less ownership
Funds ownership: 66.67% → 64.91% (-1.8%)
12% less funds holding
Funds holding: 81 → 71 (-10)
30% less capital inflows, than outflows
Capital inflows: $14.5M | Capital outflows: $20.8M
32% less call options, than puts
Call options by funds: $89K | Put options by funds: $130K
53% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$2.14M |
| 2 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$1.97M |
| 3 |
Granahan Investment Management
Waltham,
Massachusetts
|
+$1.92M |
| 4 |
Silverback Asset Management
Chapel Hill,
North Carolina
|
+$1.7M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$4.35M |
| 2 |
New York State Common Retirement Fund
Albany,
New York
|
-$2.95M |
| 3 |
Ariel Investments
Chicago,
Illinois
|
-$2.26M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$1.25M |
| 5 |
Amtrust Financial Services
New York
|
-$1.22M |
KIN Hedge Fund Activity: Q4 2018 in Review
71 of the 4,504 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences (KIN) for Q4 2018, worth a combined $241M — down 23% from $314M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of KIN and 9 opened new positions — a net loss of 10 holders — while 22 trimmed existing stakes and 27 added.
The largest buyer was Assenagon Asset Management, opening a new position worth an estimated $2.14M. The largest seller was Morgan Stanley, cutting an estimated $4.35M.
- 71 institutional investors held Kindred Biosciences (KIN) as of Q4 2018, down from 81 in Q3 2018.
- Funds reported $241M of Kindred Biosciences stock for Q4 2018, down 23% quarter-over-quarter.
- 9 funds opened new Kindred Biosciences positions in Q4 2018 and 19 closed out, a net change of -10 holders.
- The largest Kindred Biosciences buyer in Q4 2018 was Assenagon Asset Management, an estimated $2.14M added.
- The largest Kindred Biosciences seller in Q4 2018 was Morgan Stanley, an estimated $4.35M sold.
Based on aggregated 13F filings for Q4 2018.